Quality and safety issues related to traditional animal medicine: role of taurine.
BACKGROUND
Calculus Bovis (:C.Bovis) is one of the most precious and commonly-used medicinal materials in Japan and China. As the natural occurrence is very rare, a source of supply for C. Bovis is far behind the actual need and great efforts have been taken for some substitutes of natural C. Bovis. Unfortunately, very little information is available on the quality and/or clinical efficacy of medication based on C. Bovis. To ensure sustainable use of traditional therapeutic agents derived from C. Bovis, we felt that several issues needed to be addressed: 1) the source of the C. Bovis materials and quality control; 2) the role of taurine in the efficacy of C. Bovis.


METHODS
Nine samples of natural C. Bovis and its substitutes were collected. ICP-MS was used for elemental analysis and the characterization was performed by principal component analysis (PCA) and soft independent modeling of class analogy (SIMCA) as multivariate approaches. The efficacy of C. Bovis was evaluated for morphology, viability and beating pattern on cultured cardiac myocytes and/or fibroblasts.


RESULTS
PCA and multi-elemental focus was effective in discriminating C. Bovis samples derived from different habitats. A satisfactory classification using SIMCA was obtained among Australia C. Bovis, other habitats and the substitutes. Australian samples had better batch uniformity than other habitats and were composed of fewer elements. We have used Australian C. Bovis for assessment on its bioactive compounds. Rat cardiac cells incubated with C. Bovis extract (0.01-0.1 mg/ml) maintained normal morphology, viability and beating pattern. Cardiac myocytes and fibroblasts treated for 48 h with CA (0.5 mM) or DCA (0.1 mM) caused cell injury, as reflected by changes in appearance and a reduction of viability detected by the MTS assay. In cardiomyocytes, 0.5 h exposure of CA (0.5 mM) markedly decreased the velocity ratio of beating, whereas the simultaneous addition of 1 mM taurine largely prevented the decrease.


CONCLUSIONS
The multi-elemental focus provided some references for the quality control and the efficacy of C. Bovis. Taurine partly attenuated the harmful actions of bile acids. It is plausible that the relationship between taurine and the bile acids contributes to therapeutic effect of C. Bovis.
Takahashi
Kyoko
K
The Museum of Osaka University, Toyonaka, Osaka, Japan. kyokot@museum.osaka-u.ac.jp
Azuma
Yuko
Y
Shimada
Kayoko
K
Saito
Tadashi
T
Kawase
Masaya
M
Schaffer
Stephen W
SW
D000818:Animals; D001315:Australia; D001630:Bezoars; D001647:Bile Acids and Salts / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D002417:Cattle; D002478:Cells, Cultured; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D008519:Medicine, Traditional; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D025341:Principal Component Analysis; D011786:Quality Control; D051381:Rats; D017208:Rats, Wistar; D013654:Taurine / Q000378:metabolism*
D001647:Bile Acids and Salts; D013654:Taurine
Anal Sci. 2004 May;20(5):871-7
15171297
J Agric Food Chem. 2010 Feb 10;58(3):1986-92
20063888
Clin Sci (Lond). 2002 Aug;103(2):191-200
12149111
Exp Clin Cardiol. 2008 Summer;13(2):57-65
19343117
Chin Med J (Engl). 2008 Mar 5;121(5):480
18364128
Res Commun Chem Pathol Pharmacol. 1989 Mar;63(3):317-30
2727386
An Acad Bras Cienc. 2005 Mar;77(1):33-43
15692677
Jpn J Pharmacol. 2001 Dec;87(4):289-96
11829148
Atherosclerosis. 2010 Jan;208(1):19-25
19592001
Adv Exp Med Biol. 2009;643:95-103
19239140
BJOG. 2004 Aug;111(8):867-70
15270939
Int J Pharm. 2007 Jun 7;337(1-2):169-77
17270371
Biochem Biophys Res Commun. 2004 Apr 2;316(2):484-9
15020243
Adv Exp Med Biol. 2006;583:257-63
17153610
Biochem Pharmacol. 2002 Aug 15;64(4):745-9
12167494
Chem Pharm Bull (Tokyo). 2007 Jan;55(1):128-32
17202716